DE69632236D1 - Verwendung von dha in der behandlung von dyslexie - Google Patents
Verwendung von dha in der behandlung von dyslexieInfo
- Publication number
- DE69632236D1 DE69632236D1 DE69632236T DE69632236T DE69632236D1 DE 69632236 D1 DE69632236 D1 DE 69632236D1 DE 69632236 T DE69632236 T DE 69632236T DE 69632236 T DE69632236 T DE 69632236T DE 69632236 D1 DE69632236 D1 DE 69632236D1
- Authority
- DE
- Germany
- Prior art keywords
- pct
- dyslexia
- dha
- treatment
- sec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fats And Perfumes (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9510636.5A GB9510636D0 (en) | 1995-05-25 | 1995-05-25 | Fatty acid treatment |
GB9510636 | 1995-05-25 | ||
PCT/GB1996/001265 WO1996037200A1 (en) | 1995-05-25 | 1996-05-24 | Use of dha as a pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69632236D1 true DE69632236D1 (de) | 2004-05-27 |
DE69632236T2 DE69632236T2 (de) | 2005-04-14 |
Family
ID=10775045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69632236T Expired - Fee Related DE69632236T2 (de) | 1995-05-25 | 1996-05-24 | Verwendung von dha in der behandlung von dyslexie |
Country Status (17)
Country | Link |
---|---|
US (1) | US6150411A (de) |
EP (1) | EP0774962B1 (de) |
JP (1) | JPH10503531A (de) |
KR (1) | KR970704433A (de) |
AT (1) | ATE264676T1 (de) |
AU (1) | AU722474B2 (de) |
CA (1) | CA2195979A1 (de) |
DE (1) | DE69632236T2 (de) |
DK (1) | DK0774962T3 (de) |
ES (1) | ES2217317T3 (de) |
FI (1) | FI970298A0 (de) |
GB (1) | GB9510636D0 (de) |
HK (1) | HK1012575A1 (de) |
NO (1) | NO970317D0 (de) |
PT (1) | PT774962E (de) |
WO (1) | WO1996037200A1 (de) |
ZA (1) | ZA964215B (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002527387A (ja) * | 1998-10-15 | 2002-08-27 | デーエスエム・ナムローゼ・フェンノートシャップ | Pufaサプリメント |
KR100341109B1 (ko) * | 1999-03-10 | 2002-06-20 | 이인수 | 인식력 및 기억력 증강용 식이 조성물 |
US6258846B1 (en) * | 1999-06-01 | 2001-07-10 | Drugtech Corporation | Nutritional supplements |
US7112609B2 (en) * | 1999-06-01 | 2006-09-26 | Drugtech Corporation | Nutritional supplements |
GB9918023D0 (en) | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
US6479545B1 (en) * | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
GB9923738D0 (en) | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
WO2003011873A2 (en) | 2001-07-27 | 2003-02-13 | Neptune Technologies & Bioressources Inc. | Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
US20050130937A1 (en) | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
TWI365716B (en) * | 2003-12-02 | 2012-06-11 | Suntory Holdings Ltd | Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same |
US20090215896A1 (en) * | 2004-01-19 | 2009-08-27 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
GB0813599D0 (en) * | 2008-07-24 | 2008-09-03 | Pharma Marine As | Method |
US8586567B2 (en) | 2009-10-29 | 2013-11-19 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US9216199B2 (en) | 2013-12-05 | 2015-12-22 | Buriva, LLC | Nutritional supplement containing phospholipid-DHA derived from eggs |
US9549937B2 (en) | 2013-12-05 | 2017-01-24 | Burvia, LLC. | Composition containing phospholipid-DHA and folate |
US9233114B2 (en) | 2013-12-05 | 2016-01-12 | Buriva, LLC | Dietary supplement containing phospholipid-DHA derived from eggs |
US9610302B2 (en) | 2013-12-05 | 2017-04-04 | Buriva, LLC. | Composition containing phospholipid-DHA and B vitamins |
BR112018073060A2 (pt) * | 2016-06-01 | 2019-04-09 | Nestec S.A. | composição para uso na profilaxia de doença alérgica |
WO2023102170A1 (en) * | 2021-12-02 | 2023-06-08 | The Regents Of The University Of California | Compositions and methods for inhibiting seizures |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
EP0711503A3 (de) * | 1994-11-14 | 1997-11-26 | Scotia Holdings Plc | Mit GLA und/oder DGLA angereicherte Milch |
-
1995
- 1995-05-25 GB GBGB9510636.5A patent/GB9510636D0/en active Pending
-
1996
- 1996-05-24 CA CA002195979A patent/CA2195979A1/en not_active Abandoned
- 1996-05-24 JP JP8535515A patent/JPH10503531A/ja not_active Ceased
- 1996-05-24 EP EP96919911A patent/EP0774962B1/de not_active Expired - Lifetime
- 1996-05-24 AT AT96919911T patent/ATE264676T1/de not_active IP Right Cessation
- 1996-05-24 WO PCT/GB1996/001265 patent/WO1996037200A1/en active IP Right Grant
- 1996-05-24 AU AU58277/96A patent/AU722474B2/en not_active Ceased
- 1996-05-24 ZA ZA964215A patent/ZA964215B/xx unknown
- 1996-05-24 ES ES96919911T patent/ES2217317T3/es not_active Expired - Lifetime
- 1996-05-24 DK DK96919911T patent/DK0774962T3/da active
- 1996-05-24 US US08/776,250 patent/US6150411A/en not_active Expired - Lifetime
- 1996-05-24 PT PT96919911T patent/PT774962E/pt unknown
- 1996-05-24 KR KR1019970700488A patent/KR970704433A/ko active IP Right Grant
- 1996-05-24 DE DE69632236T patent/DE69632236T2/de not_active Expired - Fee Related
-
1997
- 1997-01-24 NO NO970317A patent/NO970317D0/no not_active Application Discontinuation
- 1997-01-24 FI FI970298A patent/FI970298A0/fi unknown
-
1998
- 1998-12-18 HK HK98113985A patent/HK1012575A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69632236T2 (de) | 2005-04-14 |
ATE264676T1 (de) | 2004-05-15 |
EP0774962B1 (de) | 2004-04-21 |
FI970298A (fi) | 1997-01-24 |
AU722474B2 (en) | 2000-08-03 |
PT774962E (pt) | 2004-09-30 |
EP0774962A1 (de) | 1997-05-28 |
ES2217317T3 (es) | 2004-11-01 |
JPH10503531A (ja) | 1998-03-31 |
GB9510636D0 (en) | 1995-07-19 |
KR970704433A (ko) | 1997-09-06 |
DK0774962T3 (da) | 2004-08-09 |
WO1996037200A1 (en) | 1996-11-28 |
HK1012575A1 (en) | 1999-08-06 |
FI970298A0 (fi) | 1997-01-24 |
NO970317L (no) | 1997-01-24 |
AU5827796A (en) | 1996-12-11 |
US6150411A (en) | 2000-11-21 |
NO970317D0 (no) | 1997-01-24 |
CA2195979A1 (en) | 1996-11-28 |
ZA964215B (en) | 1996-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69632236D1 (de) | Verwendung von dha in der behandlung von dyslexie | |
ATE163913T1 (de) | Ungesättigte aliphatische dicarbonsäuren | |
DE69616376T2 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
DE3684409D1 (de) | Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose. | |
ATE186834T1 (de) | Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut | |
DE68911103D1 (de) | Verwendung von Fettsäuren zur Behandlung von myalgischer Enzephalomyelitis. | |
PT920323E (pt) | Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica | |
DE69202019D1 (de) | Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS. | |
ATE196147T1 (de) | Wachstumsdifferenzierungsfaktor-12 | |
ATE284217T1 (de) | Verwendung von sulphoquinovosyldiacylglycerols zur behandlung von entzündlichen hauterkrankungen | |
DE69314234T2 (de) | Konservierte Polysiloxanemulsion zur Behandlung von Geweben | |
DE69806622D1 (de) | Kosmetische formulierungen zur verhütung und behandlung von haarausfall | |
ATE71143T1 (de) | Verfahren zur stoffwechsel- und/oder wachstumssteigernden behandlung von mikroorganismen sowie vorrichtung zur durchfuehrung des verfahrens. | |
DE69427116D1 (de) | Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis | |
ATE136776T1 (de) | Verwendung von heptastigmin zur behandlung der zerebralen ictus | |
ATE97804T1 (de) | Verwendung von fettsaeuren zur behandlung von myalgischer enzephalomyelitis. | |
DE69319140T2 (de) | 4-guanidinobutyramid zur verbesserung des blutkreislaufs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |